At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09688 ZAI LAB
Closed 12-23 16:08:09
13.630
-0.290
-2.08%
High13.920
Low13.590
Vol5.73M
Open13.920
D1 Closing13.920
Amplitude2.37%
Mkt Cap15.27B
Tradable Cap15.27B
Total Shares1.12B
T/O78.61M
T/O Rate0.51%
Tradable Shares1.12B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Zai Lab Chief Legal Officer Frazor Titus Edmondson III Reports Disposal of Common Shares
BRIEF-Zai Lab Announces Dosing Of First Participant In Global Phase 1/1b Study Of ZL-1503, An IL-13/IL-31R Bispecific Antibody For Treatment Of Atopic Dermatitis
Zai Lab Announces Dosing of First Participant in Global Phase 1/1B Study of Zl-1503, an Il-13/Il-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.